methyl 4-bromomethyl-3-chloro-5-nitro-benzoate | 1057652-85-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-bromomethyl-3-chloro-5-nitro-benzoate
• 英文别名: Methyl 4-bromomethyl-3-chloro-5-nitrobenzoate；methyl 4-(bromomethyl)-3-chloro-5-nitrobenzoate
• CAS: 1057652-85-3
• 化学式: C₉H₇BrClNO₄
• 分子量: 308.516
• InChiKey: LOXVCYZNTIEERF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-bromomethyl-3-chloro-5-nitro-benzoate 在 copper(I) oxide 、 盐酸 、 sodium hydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 129.0h， 生成 Methyl 3-chloro-4-[3-(4-chloroanilino)-3-oxopropyl]-5-nitrobenzoate
  参考文献：
  名称：

  Orally active zwitterionic factor Xa inhibitors with long duration of action

  摘要：

  We have optimized 2-aminomethylphenylamine derivative as a factor Xa inhibitor. Several polar functional groups were introduced in the central phenyl ring, and we focused on zwitter ionic compound showing continuous inhibitory activity in oral administration test. In vitro and oral activities were improved by optimization of S1 and S4 ligands. Incorporating the interaction with S1-beta pocket enhanced in vitro factor Xa inhibitory activity to less than 1 nM. Many zwitter ionic compounds showed long duration of action and potent inhibitory activity and high AUC values in oral administration tests to monkeys. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.021
• 作为产物：
  描述：

  3,5-二硝基-4-甲基苯甲酸甲酯 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 亚硝酸特丁酯 、 (PhCOO)2O 、 铁粉 、 copper dichloride 作用下， 以 1,4-二氧六环 、 甲醇 、 四氯化碳 、 乙腈 为溶剂， 反应 1.0h， 生成 methyl 4-bromomethyl-3-chloro-5-nitro-benzoate
  参考文献：
  名称：

  Orally active zwitterionic factor Xa inhibitors with long duration of action

  摘要：

  We have optimized 2-aminomethylphenylamine derivative as a factor Xa inhibitor. Several polar functional groups were introduced in the central phenyl ring, and we focused on zwitter ionic compound showing continuous inhibitory activity in oral administration test. In vitro and oral activities were improved by optimization of S1 and S4 ligands. Incorporating the interaction with S1-beta pocket enhanced in vitro factor Xa inhibitory activity to less than 1 nM. Many zwitter ionic compounds showed long duration of action and potent inhibitory activity and high AUC values in oral administration tests to monkeys. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.021

文献信息

• HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150299188A1

  公开（公告）日：2015-10-22

  Provided is a compound having a superior FLAP inhibitory action and useful as a prophylactic or therapeutic agent for arteriosclerosis and the like, and a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present DESCRIPTION, or a salt thereof.

  提供了一种具有卓越的FLAP抑制作用并可用作动脉硬化等预防或治疗剂的化合物及其盐。本发明涉及一种由式中各符号如本说明中所定义的化合物或其盐表示的化合物。
• EP2889291
  申请人：——

  公开号：——

  公开（公告）日：——
• Orally active zwitterionic factor Xa inhibitors with long duration of action
  作者：Akiyoshi Mochizuki、Tsutomu Nagata、Hideyuki Kanno、Daisuke Takano、Masamichi Kishida、Makoto Suzuki、Toshiharu Ohta

  DOI：10.1016/j.bmcl.2011.10.021

  日期：2011.12

  We have optimized 2-aminomethylphenylamine derivative as a factor Xa inhibitor. Several polar functional groups were introduced in the central phenyl ring, and we focused on zwitter ionic compound showing continuous inhibitory activity in oral administration test. In vitro and oral activities were improved by optimization of S1 and S4 ligands. Incorporating the interaction with S1-beta pocket enhanced in vitro factor Xa inhibitory activity to less than 1 nM. Many zwitter ionic compounds showed long duration of action and potent inhibitory activity and high AUC values in oral administration tests to monkeys. (C) 2011 Elsevier Ltd. All rights reserved.